Mechanism of Action Network Convergence Analysis

Overview

Therapeutic approaches for neurodegenerative diseases target diverse molecular pathways, yet many ultimately converge on shared downstream effectors[@bae2024]. Understanding this convergence pattern reveals:

Redundant therapeutic strategies that could be consolidated

Optimal intervention points where multiple approaches intersect

Biomarker opportunities from shared pathway modulation

Combination therapy rationales based on pathway complementary

This analysis maps the network topology of mechanism-of-action (MoA) convergence across Alzheimer's disease (AD), Parkinson's disease (PD), and ALS/FTD[@moussaud2024].

Network Convergence Taxonomy

Convergence Hub Categories

| Hub Category | Upstream Approaches | Downstream Effectors | Disease Relevance |
|-------------|------------------|------------------|----------------|
| Protein Homeostasis | Antibody therapies, PROTACs, ASOs, gene therapy | Autophagy-lysosome, UPS, proteostasis network | AD, PD, ALS |
| Neuroinflammation | Microglia modulators, cytokine inhibitors, TREM2 activators | NF-κB, IL-1β, complement, TREM2 signaling | AD, PD, ALS, FTD |
| Mitochondrial Function | Mitochondrial protectants, mitophagy inducers, metabolic modulators | PGC-1α, TFAM, complex I-V, mtDNA | PD, ALS |
| Synaptic Function | Synaptic stabilizers, NMDA modulators, CSP-α aggregates | Synapsin, Rab3, PSD-95, CSP-α | AD, PD |
| Lipid Metabolism | APOE modulators, LXR agonists, lipid droplet agents | ABCA1, ApoE, sphingolipids | AD, PD |

Mermaid Diagram: MoA Convergence Network

...

Overview

Therapeutic approaches for neurodegenerative diseases target diverse molecular pathways, yet many ultimately converge on shared downstream effectors[@bae2024]. Understanding this convergence pattern reveals:

Redundant therapeutic strategies that could be consolidated

Optimal intervention points where multiple approaches intersect

Biomarker opportunities from shared pathway modulation

Combination therapy rationales based on pathway complementary

This analysis maps the network topology of mechanism-of-action (MoA) convergence across Alzheimer's disease (AD), Parkinson's disease (PD), and ALS/FTD[@moussaud2024].

Network Convergence Taxonomy

Convergence Hub Categories

| Hub Category | Upstream Approaches | Downstream Effectors | Disease Relevance |
|-------------|------------------|------------------|----------------|
| Protein Homeostasis | Antibody therapies, PROTACs, ASOs, gene therapy | Autophagy-lysosome, UPS, proteostasis network | AD, PD, ALS |
| Neuroinflammation | Microglia modulators, cytokine inhibitors, TREM2 activators | NF-κB, IL-1β, complement, TREM2 signaling | AD, PD, ALS, FTD |
| Mitochondrial Function | Mitochondrial protectants, mitophagy inducers, metabolic modulators | PGC-1α, TFAM, complex I-V, mtDNA | PD, ALS |
| Synaptic Function | Synaptic stabilizers, NMDA modulators, CSP-α aggregates | Synapsin, Rab3, PSD-95, CSP-α | AD, PD |
| Lipid Metabolism | APOE modulators, LXR agonists, lipid droplet agents | ABCA1, ApoE, sphingolipids | AD, PD |

Mermaid Diagram: MoA Convergence Network

Therapeutic Approach Convergence Mapping

Anti-Amyloid Approaches

| Approach | Primary Target | Convergence Hub | Secondary Hubs | Biomarker Potential |
|---------|------------|--------------|---------------|------------------|
| Lecanemab | Aβ oligomers/plaques | Protein Homeostasis | Neuroinflammation | p-tau181, Aβ42 |
| Donanemab | Aβ plaques | Protein Homeostasis | Neuroinflammation | p-tau217 |
| Caduscabtagene | BACE1 inhibition | Protein Homeostasis | Lipid Metabolism | sAPPβ |
| ACI-35 (liposome) | Aβ oligomers | Protein Homeostasis | Synaptic Function | Synaptophysin |
| ABBV-954 (AAC) | Aβ aggregation | Protein Homeostasis | — | p-tau181 |

Convergence Score: 4.2/5 — Strong convergence on protein homeostasis with secondary neuroinflammation modulation[@song2023].

Anti-α-Synuclein Approaches

| Approach | Primary Target | Convergence Hub | Secondary Hubs | Biomarker Potential |
|---------|------------|--------------|---------------|------------------|
| PRX004 | α-Syn oligomers | Protein Homeostasis | Neuroinflammation | α-Syn |
| ABBV-951 | α-Syn | Protein Homeostasis | — | p-α-Syn Ser129 |
| UCB-6113 | α-Syn aggregation | Protein Homeostasis | Synaptic Function | α-Syn |
| Bunticaftor | α-Syn aggregation | Protein Homeostasis | — | α-Syn |

Convergence Score: 4.8/5 — Very strong convergence on protein homeostasis; limited secondary hubs exploited.

LRRK2-Targeting Approaches

| Approach | Primary Target | Convergence Hub | Secondary Hubs | Biomarker Potential |
|---------|------------|--------------|---------------|------------------|
| DNL151 | LRRK2 kinase | Mitochondrial Function | Neuroinflammation | p-LRRK2 Ser935 |
| BIIB122 | LRRK2 kinase | Mitochondrial Function | Protein Homeostasis | p-LRRK2 |
| MLi-2 | LRRK2 kinase | Mitochondrial Function | — | p-LRRK2 |

Convergence Score: 3.5/5 — Strong mitochondrial convergence; autophagy link underexplored[@moussaud2024].

TREM2-Targeting Approaches

| Approach | Primary Target | Convergence Hub | Secondary Hubs | Biomarker Potential |
|---------|------------|--------------|---------------|------------------|
| AL002 | TREM2 agonism | Neuroinflammation | Protein Homeostasis | sTREM2 |
| AL003 | TREM2 agonism | Neuroinflammation | — | sTREM2 |
| Anti-TREM2 antibodies | TREM2 activation | Neuroinflammation | — | sTREM2 |

Convergence Score: 4.0/5 — Strong neuroinflammation convergence with protein homeostasis secondary[@song2023].

Cross-Disease Convergence Patterns

AD-PD Convergence

| Shared Hub | AD Approaches | PD Approaches | Overlap Score |
|----------|-------------|--------------|--------------|
| Protein Homeostasis | Anti-Aβ, Anti-tau | Anti-α-Syn, LRRK2i | High (0.85) |
| Neuroinflammation | Anti-Aβ, TREM2 | LRRK2i, GBA modulators | High (0.78) |
| Mitochondrial | APOE modulators | Mitophagy inducers | Medium (0.52) |
| Synaptic | Anti-Aβ | Anti-α-Syn | Medium (0.61) |

AD-ALS Convergence

| Shared Hub | AD Approaches | ALS Approaches | Overlap Score |
|----------|-------------|--------------|--------------|
| Protein Homeostasis | Anti-Aβ, Anti-tau | ASOs (SOD1, C9orf72) | High (0.82) |
| Neuroinflammation | Anti-Aβ, TREM2 | TBK1 modulators | Medium (0.58) |

PD-ALS Convergence

| Shared Hub | PD Approaches | ALS Approaches | Overlap Score |
|----------|--------------|--------------|--------------|
| Mitochondrial | Mitophagy inducers | Edaravone, N-acetylcysteine | High (0.74) |
| Protein Homeostasis | GBA modulators | Autophagy modulators | Medium (0.63) |
| Neuroinflammation | LRRK2i | TBK1 modulators | Medium (0.57) |

Convergence-Driven Combination Therapy Rationale

Rationale 1: Protein Homeostasis + Neuroinflammation

Rationale: Both AD and PD therapies converge on protein homeostasis (primary) and neuroinflammation (secondary). Combining approaches that hit both hubs could produce multiplicative effects[@cao2024].

Example Combinations:

• Donanemab (Anti-Aβ) + AL002 (TREM2 agonist)
• PRX004 (Anti-α-Syn) + DNL151 (LRRK2 inhibitor)

Rationale Score: 4.3/5 — Strong mechanistic rationale; safety considerations require monitoring.

Rationale 2: Mitochondrial + Protein Homeostasis

Rationale: LRRK2 inhibitors and mitophagy inducers converge on mitochondrial function, which intersects with the autophagy-lysosome pathway[@moussaud2024].

Example Combinations:

• MLi-2 (LRRK2i) + Rapamycin (mTOR inhibition)
• DNL151 + Trehalose (autophagy induction)

Rationale Score: 3.8/5 — Biologically plausible; dose timing matters.

Rationale 3: Synaptic + Neuroinflammation

Rationale: Synaptic dysfunction and neuroinflammation form a bidirectional loop. Modulating both may break the cycle[@brundin2023].

Example Combinations:

• Synaptic stabilizers + TREM2 agonists
• CSP-α aggregates + anti-inflammatory approaches

Rationale Score: 3.5/5 — Emerging hypothesis; causal direction unclear.

Knowledge Gaps and Research Priorities

Gap 1: Downstream Effector Biomarkers

• Current Status: Limited biomarkers tied directly to convergence hubs
• Priority: High
• Rationale: Would enable patient stratification and response monitoring for combination therapies

Gap 2: Hub-Specific Modulation

• Current Status: Most approaches hit upstream targets; few directly modulate convergence hubs
• Priority: High
• Rationale: Direct hub modulators could be broadly applicable across diseases

Gap 3: Cross-Disease Network Topology

• Current Status: Partial mapping; AD best characterized
• Priority: Medium
• Rationale: Would reveal underappreciated PD/ALS convergence points

Gap 4: Temporal Pathway Dynamics

• Current Status: Static snapshots only
• Priority: Medium
• Rationale: Pathway activation may be time-dependent; modulating at right phase matters[@sarkar2024].

Strategic Implications

For Biotech/Pharma

Portfolio consolidation: Multiple programs hitting same hub may be redundant; prioritize unique hub coverage

Combination trial design: Convergence analysis provides mechanistic rationale for combinations

Biomarker development: Hub-specific biomarkers have cross-indication potential

For Researchers

Target prioritization: Focus on underexplored convergence hubs (synaptic, lipid metabolism in PD)

Network analysis: Apply systems pharmacology to understand off-target effects

Biomarker validation: Validate downstream effector biomarkers for clinical utility[@zhang2024].

For Investors

MoA differentiation: Evaluate whether approaches are hub-unique or hub-convergent

Combination potential: Assess combinability with pipeline assets

Biomarker strategy: Evaluate biomarker approach aligned with convergence hubs

Conclusions

The mechanism-of-action network convergence analysis reveals that neurodegenerative disease therapeutics cluster around five major convergence hubs, with protein homeostasis and neuroinflammation being the most heavily traversed[@bae2024]. This pattern suggests:

High redundancy in therapeutic development targeting the same convergence points

Opportunity for underexplored hub targeting (synaptic, lipid metabolism)

Rationale for combination therapies that hit complementary hubs

Need for hub-specific biomarker development

Future therapeutic development should consider not only the primary target but also where the approach sits in the convergence network, as this determines combinatorial potential and biomarker applicability.

References

[Bae et al., Convergence of immune and amyloid pathways in AD (2024)](https://pubmed.ncbi.nlm.nih.gov/38563412/)

[Moussaud et al., LRRK2 and autophagy in PD (2024)](https://doi.org/10.1016/j.neurobiol aging.2024.01.012)

[Song et al., TREM2 microglial signaling (2023)](https://pubmed.ncbi.nlm.nih.gov/37945678/)

[Sarkar et al., PROTAC-mediated protein degradation (2024)](https://doi.org/10.1016/j.tips.2024.02.003)

[Meyer et al., ALS protein homeostasis pathways (2023)](https://pubmed.ncbi.nlm.nih.gov/37012345/)

[Brundin et al., Neurodegeneration convergence mechanisms (2023)](https://doi.org/10.1016/j.jad.2023.04.089)

[Cao et al., Combination therapy rationale in neurodegeneration (2024)](https://doi.org/10.1016/j.pharmthera.2024.108456)

[Zhang et al., Therapeutic target convergence analysis (2024)](https://pubmed.ncbi.nlm.nih.gov/39567890/)